Speaking today (Tuesday 31 October) at the White Rose Bioscience Forum in York, Adams encourages companies to consider both their strengths and weaknesses, and to be open to all potential collaborations to ensure a healthy product portfolio.
“My advice is: be flexible, think out the box; what you can offer as company? Think about what you’ve got, be it technology or know how, and think hard about how you can capitalise on it. The whole company can contribute to this – talk to the research group and ask what else could we do with this technology, or put with this technology, and who could we talk to that they have contacts with? You’ll be surprised how many potential opportunities are generated from this creative brainstorming.”
This advice is based on Antisoma’s own experience. The company does not have a discovery arm; most of what it does is licensed directly from academia or from other biotechs, so it has to be creative in forging the right alliances to create a thriving product pipeline.
“Preclinically our focus is biology and we have enormous expertise in this area,” says Adams. This strength is very attractive to companies whose expertise lies on the chemistry side who have products that need biology.”
Since most cancer therapies around today are derived from plants, Antisoma was very interested to hear from a company contact about a young Australian company, Ecobiotics. Its expertise lay in its knowledge of the different chemical properties of Queensland rainforest plants at various stages of the plants’ growth. Says Adams: “Ecobiotics researchers knew how to select and synthesise the chemicals from various rainforest plants, but lacked the biological expertise, cancer models and in vitro capability.”
Antisoma and Ecobiotics now have a fruitful collaboration underpinned by a simple and transparent agreement.
“No money was exchanged up front and there are no unnecessary legal complexities. They provide us with molecules that display anti-cancer properties, we test them, and all resulting data is shared. Whilst Ecobiotics owns the IP, Antisoma has the right to select up to two molecule classes each year for development. All other test results on other molecules are owned by Ecobiotics which is free to develop the molecule further or offer it to other parties. It’s a perfect solution – they have the chemistry and we have the biology.
"I liken our networking approach to creating a spider’s web down whose strands products can come, whether developed in house, through collaborations or licensed in. The more strands you have the more chance you have of getting products to feed into your pipeline,” he says.
Jo Kelly | alfa
How Strong Brands Translate into Money
15.11.2016 | Kühne Logistics University - Wissenschaftliche Hochschule für Logistik und Unternehmensführung
Demographic change depresses tax revenues
04.11.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Materials Sciences
06.12.2016 | Medical Engineering
06.12.2016 | Power and Electrical Engineering